Zoetis (ZTS) Set to Announce Earnings on Thursday

Zoetis (NYSE:ZTS) will be releasing its earnings data before the market opens on Thursday, May 2nd. Analysts expect Zoetis to post earnings of $1.35 per share for the quarter. Zoetis has set its FY24 guidance at $5.74 to $5.84 EPS and its FY 2024 guidance at 5.740-5.840 EPS.Individual that wish to listen to the company’s earnings conference call can do so using this link.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing the consensus estimate of $1.32 by ($0.08). Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The business had revenue of $2.21 billion for the quarter, compared to analysts’ expectations of $2.19 billion. During the same quarter in the prior year, the business posted $1.15 earnings per share. The business’s revenue for the quarter was up 8.5% on a year-over-year basis. On average, analysts expect Zoetis to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Zoetis Stock Performance

Shares of ZTS opened at $159.17 on Wednesday. The business’s fifty day simple moving average is $170.66 and its two-hundred day simple moving average is $179.12. The company has a current ratio of 3.36, a quick ratio of 2.00 and a debt-to-equity ratio of 1.32. Zoetis has a 12 month low of $144.80 and a 12 month high of $201.92. The company has a market cap of $72.80 billion, a price-to-earnings ratio of 31.39, a P/E/G ratio of 2.42 and a beta of 0.85.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be issued a dividend of $0.432 per share. The ex-dividend date is Thursday, April 18th. This represents a $1.73 annualized dividend and a dividend yield of 1.09%. Zoetis’s payout ratio is 34.12%.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. StockNews.com cut Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. Piper Sandler reaffirmed an “overweight” rating and issued a $195.00 target price (down from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. The Goldman Sachs Group raised their target price on Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a report on Wednesday, January 17th. Stifel Nicolaus decreased their target price on Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, Barclays decreased their target price on Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a report on Tuesday, April 23rd. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $216.13.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 923 shares of the business’s stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $151.17, for a total value of $139,529.91. Following the completion of the sale, the executive vice president now owns 14,800 shares in the company, valued at $2,237,316. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders sold 2,209 shares of company stock worth $371,293. Corporate insiders own 0.16% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.